Production and Chemical Separation of No Carrier Added (nca) Lutetium-177
نویسندگان
چکیده
منابع مشابه
Comparative studies of extraction chromatography and electro-amalgamation separation to produce no-carrier added 177Lu by Tehran research reactor
Introduction:Owing to its favorable radionuclidic characteristics, such as tl/2 = 6.73 day and Eβ (max) = 497 keV and ease of its large-scale production using medium flux research reactors, lutetium-177 (177Lu) is an attractive radionuclide for various therapeutic applications. No carrier added (NCA) 177Lu was obtained by thermal neut...
متن کاملTargetry for cyclotron production of no-carrier-added cadmium-109 from natAg(p,n)109Cd reaction
Background: Solid targets that consist of powder and electrodeposited targets are used commonly to produce radionuclides by accelerators. Since silver is easily electrodeposited in cyanide baths and has a very excellent thermal conductivity, the electrodeposited target is preferable to produce 109Cd. To avoid cracking or peeling of the target during bombardment, it should have a level surface a...
متن کاملProduction of no-carrier-added Ho-166 for targeted therapy purposes
Introduction:Holmium-166 radionuclide is one of the most effective radionuclides used for targeted therapy with theranostic properties. One method to produce this radioisotope is via the decay of its parent (indirect method). In this study applicability of extraction chromatography (EXC) for separation of no carrier added 166Ho from neutron-irradiated natura...
متن کاملLutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
OBJECTIVES Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 ((90)Y) and lutetium-177 ((177)Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We repor...
متن کاملLutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Imaging and Radiation Sciences
سال: 2019
ISSN: 1939-8654
DOI: 10.1016/j.jmir.2019.03.126